Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function (clinicaltrials.gov) - Oct 24, 2026 - P1 | N=16 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting
Enrollment open • Renal Disease
|